Clinigen Licenses Commercialization Rights for Proleukin from Novartis in the US

Shots:

• Novartis to receive $210M as total deal value, including $120M upfront, $60M deferred payment for 12mos. and $30M milestone on sales of product. Clinigen to get commercialization rights for Novartis’ Proleukin in the US and WW license for Proleukin
• The focus of the agreement is to develop and commercialize Proleukin and strengthen Clinigen’s immune-oncology portfolio with expansion of footprints in the US
• Proleukin (aldesleukin, human recombinant IL-2) is a synthetic protein acts similarily as nterleukin-2 (IL-2) involved in activating WBCs and is being evaluated in 80 trials in the US for multiple therapy areas

Click here to read full press release/ article | Ref: Clinigen | Image: Pharmacy Research UK